Top-Rated StocksTop-RatedNASDAQ:RAPP Rapport Therapeutics (RAPP) Stock Price, News & Analysis $43.62 0.00 (0.00%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$43.53 -0.09 (-0.21%) As of 09/11/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Rapport Therapeutics Stock (NASDAQ:RAPP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rapport Therapeutics alerts:Sign Up Key Stats Today's Range$43.01▼$44.3050-Day Range$38.57▼$52.5052-Week Range$22.73▼$52.93Volume251,786 shsAverage Volume275,788 shsMarket Capitalization$2.09 billionP/E RatioN/ADividend YieldN/APrice Target$62.86Consensus RatingBuy Company Overview Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for disorders of the central nervous system. The company’s research centers on receptor-associated proteins, which help regulate neurotransmitter receptors and may provide opportunities to develop more selective therapies than those that target receptors broadly. Rapport’s lead development program, RAP-219, is an orally administered investigational therapy designed to modulate AMPA receptors through their associated proteins. The program is being evaluated for focal epilepsy and may have potential applications in other neurological and psychiatric disorders. As an investigational medicine, RAP-219 has not been approved for commercial use. Rapport was established in 2018 with backing from PureTech Health and became a publicly traded company on the Nasdaq in 2024. The company is headquartered in Boston, Massachusetts, and its research and development activities are directed toward addressing significant unmet needs in neurological disease. Rapport Therapeutics is led by President and Chief Executive Officer Don Nicholson.AI Generated. May Contain Errors. Read More Rapport Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreRAPP MarketRank™: Rapport Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 409th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingRapport Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialRapport Therapeutics has a consensus price target of $62.86, representing about 44.1% upside from its current price of $43.62.Amount of Analyst CoverageRapport Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rapport Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Rapport Therapeutics are expected to decrease in the coming year, from ($4.09) to ($4.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rapport Therapeutics is -14.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rapport Therapeutics is -14.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRapport Therapeutics has a P/B Ratio of 4.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rapport Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.32% of the float of Rapport Therapeutics has been sold short.Short Interest Ratio / Days to CoverRapport Therapeutics has a short interest ratio ("days to cover") of 8.23.Change versus previous monthShort interest in Rapport Therapeutics has recently increased by 0.36%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRapport Therapeutics does not currently pay a dividend.Dividend GrowthRapport Therapeutics does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.02 News SentimentRapport Therapeutics has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Rapport Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for RAPP on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Rapport Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rapport Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,858,615.00 in company stock.Percentage Held by Insiders12.48% of the stock of Rapport Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsRapport Therapeutics has minimal institutional ownership at this time.Read more about Rapport Therapeutics' insider trading history. Receive RAPP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rapport Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RAPP Stock News HeadlinesInsider Selling: Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $374,458.10 in StockSeptember 10, 2026 | insidertrades.comRapport Therapeutics, Inc. (NASDAQ:RAPP) Receives $62.86 Consensus Target Price from BrokeragesSeptember 6, 2026 | americanbankingnews.comThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percent run, and Nvidia before it climbed more than 50,000 percent. Now Chaikin says a new AI data center technology using 99 percent less electricity, water, and space could accelerate scientific breakthroughs 360-fold, and one company behind it just flashed bullish in his system. See the full research and the ticker Chaikin is watching before this presentation goes offline. | Chaikin Analytics (Ad)Rapport Therapeutics to Participate in Upcoming Investor ConferencesSeptember 2, 2026 | globenewswire.comInsider Selling: Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $937,913.97 in StockAugust 27, 2026 | insidertrades.comRapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical ProgramAugust 24, 2026 | globenewswire.comRapport Therapeutics: A 22-Day Half-Life Creates A Differentiated Epilepsy FranchiseAugust 21, 2026 | seekingalpha.comInsider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $20,159.60 in StockAugust 21, 2026 | insidertrades.comSee More Headlines RAPP Stock Analysis - Frequently Asked Questions How have RAPP shares performed this year? Rapport Therapeutics' stock was trading at $30.34 at the beginning of 2026. Since then, RAPP shares have increased by 43.8% and is now trading at $43.62. How were Rapport Therapeutics' earnings last quarter? Rapport Therapeutics, Inc. (NASDAQ:RAPP) posted its quarterly earnings results on Wednesday, August, 5th. The company reported ($1.19) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by $0.07. When did Rapport Therapeutics IPO? Rapport Therapeutics (RAPP) raised $136 million in an IPO on Friday, June 7th 2024. The company issued 8,000,000 shares at a price of $17.00 per share. Who are Rapport Therapeutics' major shareholders? Rapport Therapeutics' top institutional investors include TRV GP V LLC (13.09%), ARCH Venture Management LLC (7.77%), BlackRock Inc. (5.64%) and Johnson & Johnson (3.73%). Insiders that own company stock include Rock Ventures V LP Third, Abraham Ceesay, David Bredt, Krishnaswamy Yeleswaram, Cheryl Gault, James Healy, Troy A Ignelzi and Wendy B Young. View institutional ownership trends. How do I buy shares of Rapport Therapeutics? Shares of RAPP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rapport Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rapport Therapeutics investors own include Alpha Metallurgical Resources (AMR), Global X Copper Miners ETF (COPX), Hims & Hers Health (HIMS), Karuna Therapeutics (KRTX), Navios Maritime Partners (NMM). Company Calendar Last Earnings8/05/2026Today9/13/2026Status update9/22/2026TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit9/23/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 RAPP's financial health is in the Green zone, according to TradeSmith. RAPP has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RAPP Previous SymbolNASDAQ:RAPP CIK2012593 Webwww.rapportrx.com Phone(857) 321-8020FaxN/AEmployees84Year Founded2022Price Target and Rating Average Price Target for Rapport Therapeutics$62.86 High Price Target$80.00 Low Price Target$46.00 Potential Upside/Downside+44.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$111.48 million Net MarginsN/A Pretax Margin-685.80% Return on Equity-29.02% Return on Assets-27.37% Debt Debt-to-Equity RatioN/A Current Ratio15.72 Quick Ratio15.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.17 per share Price / Book4.29Miscellaneous Outstanding Shares47,980,000Free Float41,990,000Market Cap$2.09 billion OptionableN/A Beta1.02 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:RAPP) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | Sponsoredyour job is on the listThe CEO of one of the largest AI labs on earth said it plainly: AI could wipe out half of all entry-level whit...Behind the Markets | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
